Capacity Expansion Samsung Biologics is aggressively expanding production capacity with Plants 1–5 operating at full or ramping capacity and plans for second bio campus expansion, signaling ongoing demand and a need for scalable CDMO services and manufacturing partnerships.

M&A Financing The company is pursuing a large rights offering to fund strategic acquisitions, including PolyPeptide, indicating a growth-by-acquisition strategy that may create integration opportunities for partner CDMOs and accelerators in peptide and related biologics segments.

Conjugation Growth Plans to introduce ADC drug product services and existing conjugation process development capabilities suggest rising need for specialized bioconjugation expertise, analytical, and formulation support to attract partners developing antibody–drug conjugates.

Global Outreach Active presence at industry events like BPI Boston and BioProcess International, combined with a claimed fastest throughput and large capacity, positions Samsung Biologics as a compelling partner for biopharma companies seeking rapid scale-up and global CDMO collaboration.

Financial Momentum Recent Q3 2026 revenue figures near KRW 1.49 trillion with strong plant utilization and rising contributions from new facilities imply a robust financial profile, enabling more strategic investments in partnerships, capacity contracts, and long-term development programs.